Core Insights - BioTissue Holdings, Inc. has completed the sale of its non-ocular Surgical and Wound Care business to BioStem Technologies, Inc., allowing BioTissue to focus on ocular market leadership and innovation in eye care solutions [1][2][3] Company Overview - BioTissue specializes in utilizing human birth tissue for regenerative healing, particularly in treating acute and chronic ocular surface conditions [4] - The company has developed a portfolio of cryopreserved amniotic membrane products using proprietary CryoTek® technology, which preserves the tissue's structural and functional integrity [4] - BioTissue has conducted over 1 million human procedures with its products and has over 420 peer-reviewed publications supporting its technology [4] Strategic Focus - Following the divestiture, BioTissue will concentrate on advancing interventional therapies for ocular conditions, including products like Prokera, CAM360 AmnioGraft, and AmnioGuard [2][3] - The company aims to prioritize product innovation, professional education, and comprehensive customer support within the eye care market [2] Partnership with BioStem - BioStem Technologies will acquire exclusive rights to BioTissue's Neox and Clarix product lines, integrating BioTissue's surgical sales team into its commercial organization [2][3] - BioStem's CEO highlighted the complementary strengths of BioTissue's portfolio to their existing business, indicating a strong potential for growth and improved patient outcomes [3]

Core Viewpoint - BioStem Technologies, Inc. has acquired the surgical and wound care business of BioTissue Holdings Inc. for approximately $15 million, enhancing its commercial organization and expanding its market reach in advanced wound care [1][4][5]. Group 1: Acquisition Details - BioStem has closed a definitive asset purchase agreement with BioTissue, acquiring its full portfolio of surgical and wound care assets, including the Neox and Clarix product lines [2][3]. - The acquisition includes a nationwide network of sales representatives and independent agents, along with key GPO contracts, significantly expanding BioStem's commercial capabilities [2][3]. - The total upfront cash payment for the acquisition is approximately $15 million, with potential additional payments of up to $25 million based on regulatory and commercial milestones [4][5]. Group 2: Financial Impact - The acquired assets generated approximately $29 million in sales in 2025 and are expected to contribute positively to BioStem's EBITDA in 2026 [5]. - Post-acquisition, BioStem's cash and restricted cash balance is approximately $16 million [5]. Group 3: Leadership Changes - Barry Hassett has been promoted to Chief Commercial Officer to lead the newly combined commercial team, bringing over 25 years of industry experience [6].